Clinic
Christus Good Shepherd Medical Center
Christus Good Shepherd Medical Center was paid $44.20M by Medicaid between May 2019 and Dec 2024, across 169 billing codes. Its largest line is 99284, emergency room visit (serious) — 44% of everything it billed.
33Billing provider infoCHRISTUS GOOD SHEPHERD MEDICAL CENTER
LONGVIEW, TX 75601
LONGVIEW, TX 75601
33aNPI1124092036assigned 02/15/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$44.20M
24GClaims406,517
24DCodes billed169
24AFirst – last monthMay 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#12 of 320
Median peer was paid$205K
This provider vs. median216×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 332 | $13K | |
| 2020 | 9,800 | $625K | |
| 2021 | 88,343 | $4.12M | |
| 2022 | 131,098 | $16.32M | |
| 2023 | 119,487 | $17.38M | |
| 2024incomplete | 57,457 | $5.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 24,403 | 22,246 | $19.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 66,247 | 63,927 | $6.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 2,692 | 2,481 | $4.65M |
| 87428 | 3.4% | 22,824 | 22,260 | $1.49M | |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.0% | 706 | 679 | $1.31M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 17,273 | 16,905 | $1.27M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 7,186 | 6,649 | $812K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.6% | 14,801 | 13,941 | $687K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 13,756 | 12,910 | $677K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 15,804 | 15,452 | $665K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 3,902 | 3,480 | $494K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 11,086 | 5,445 | $465K |
157 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 3,280 | $445K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,443 | $437K |
| 80053 | Comprehensive metabolic panel | <1% | 23,379 | $358K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,168 | $351K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 79 | $338K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,828 | $312K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,539 | $272K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 181 | $253K |
| 87081 | <1% | 12,777 | $202K | |
| G0378 | Hospital observation service, per hour | <1% | 377 | $148K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,639 | $133K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 907 | $124K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,102 | $119K |
| 81025 | <1% | 7,553 | $119K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 96 | $110K |
| 81001 | <1% | 20,993 | $107K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 125 | $105K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,362 | $86K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 665 | $67K |
| 87807 | <1% | 1,629 | $67K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,061 | $64K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,061 | $64K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 690 | $58K |
| 83880 | <1% | 2,079 | $58K | |
| 84484 | <1% | 4,840 | $51K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,027 | $47K |
| 87430 | <1% | 2,369 | $47K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,413 | $46K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 258 | $44K |
| 86850 | <1% | 657 | $43K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 789 | $38K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 798 | $32K |
| 87420 | <1% | 993 | $27K | |
| 87800 | <1% | 337 | $26K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 348 | $24K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 798 | $23K |
| 83690 | <1% | 2,793 | $23K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 662 | $23K |
| 73610 | <1% | 228 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 646 | $22K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 899 | $18K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 70 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,651 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,205 | $16K |
| 73630 | <1% | 237 | $15K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 139 | $14K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 228 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,617 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,569 | $13K |
| 86780 | <1% | 585 | $12K | |
| 82805 | <1% | 216 | $11K | |
| 80061 | Lipid panel | <1% | 1,761 | $11K |
| 83605 | <1% | 1,161 | $10K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 428 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,774 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 468 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,379 | $8K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 91 | $8K |
| 73030 | <1% | 174 | $8K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 294 | $6K |
| 84702 | <1% | 544 | $6K | |
| 73562 | <1% | 110 | $6K | |
| 81003 | <1% | 1,703 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 30 | $6K |
| 73502 | <1% | 148 | $5K | |
| 87040 | <1% | 718 | $5K | |
| 87186 | <1% | 1,061 | $5K | |
| 72100 | <1% | 99 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 119 | $5K |
| 80320 | <1% | 211 | $5K | |
| 82077 | <1% | 279 | $4K | |
| 74018 | <1% | 144 | $4K | |
| 83735 | <1% | 1,141 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 117 | $4K |
| 85610 | <1% | 1,337 | $4K | |
| 80329 | <1% | 76 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $4K |
| 11721 | <1% | 249 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,509 | $3K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 36 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 532 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,644 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 788 | $3K |
| 87077 | <1% | 750 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 76 | $3K |
| 80055 | <1% | 33 | $3K | |
| 80143 | <1% | 156 | $3K | |
| 74022 | <1% | 12 | $3K | |
| 85730 | <1% | 643 | $3K | |
| 80179 | <1% | 143 | $2K | |
| 85379 | <1% | 192 | $2K | |
| 90715 | <1% | 15 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,321 | $2K |
| 86900 | <1% | 894 | $2K | |
| 86803 | <1% | 215 | $2K | |
| 86901 | <1% | 877 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 31 | $2K |
| 84439 | <1% | 417 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 319 | $1K |
| 86738 | <1% | 124 | $1K | |
| 88142 | <1% | 25 | $1K | |
| 82550 | <1% | 266 | $1K | |
| 76801 | <1% | 18 | $1K | |
| 73130 | <1% | 19 | $1K | |
| 76642 | <1% | 13 | $978.99 | |
| 20610 | <1% | 16 | $901.01 | |
| 82043 | <1% | 353 | $800.07 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 40 | $730.18 |
| 87070 | <1% | 27 | $727.45 | |
| 80047 | <1% | 56 | $503.97 | |
| 99152 | <1% | 15 | $475.67 | |
| 86762 | <1% | 70 | $457.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 17 | $428.71 |
| 86328 | <1% | 27 | $426.61 | |
| 94761 | <1% | 16 | $392.32 | |
| 82565 | <1% | 122 | $369.97 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 109 | $328.06 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $326.82 |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $322.21 |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,917 | $320.14 |
| 90686 | <1% | 122 | $296.48 | |
| 87340 | <1% | 49 | $287.91 | |
| 82570 | <1% | 123 | $279.82 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 271 | $227.22 |
| 82950 | <1% | 43 | $181.36 | |
| C1769 | Guide wire | <1% | 158 | $176.97 |
| 93971 | <1% | 12 | $151.67 | |
| 81002 | <1% | 47 | $144.99 | |
| 84703 | <1% | 15 | $123.47 | |
| 96376 | <1% | 547 | $121.78 | |
| 82962 | <1% | 4,978 | $119.08 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 15 | $105.77 |
| 86703 | <1% | 13 | $94.12 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $85.97 |
| 85014 | <1% | 58 | $68.39 | |
| 92567 | <1% | 12 | $64.06 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 29 | $61.31 |
| 84132 | <1% | 13 | $52.53 | |
| 87147 | <1% | 27 | $49.39 | |
| 85652 | <1% | 28 | $45.71 | |
| 86140 | <1% | 16 | $38.57 | |
| 84100 | <1% | 13 | $31.02 | |
| 80069 | <1% | 36 | $30.00 | |
| A9270 | Non-covered item or service | <1% | 294 | $23.13 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 18 | $17.18 |
| 88720 | <1% | 14 | $16.88 | |
| 85018 | <1% | 42 | $9.31 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 1,492 | $0.00 |
| 90662 | 0% | 87 | $0.00 | |
| 97803 | 0% | 30 | $0.00 | |
| 80164 | 0% | 14 | $0.00 | |
| 36592 | 0% | 31 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 181 | $0.00 |
| 0001A | 0% | 62 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 15 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 14 | $0.00 |
| C1755 | Catheter, intraspinal | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, NORMAN (CEO)
Parent organizationCHRISTUS HEALTH
| Provider | Location | Paid |
|---|---|---|
| Christus Good Shepherd Medical Center | Marshall, TX | $44K |
| Christus Good Shepherd Medical Center | Marshall, TX | $7.81 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.